Vaxcyte, Inc. (PCVX) Financials
PCVX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.4 billion | 167.4 million |
| 2023-09-30 | 1.5 billion | 93.3 million |
| 2023-06-30 | 1.5 billion | 69.4 million |
| 2023-03-31 | 1.0 billion | 63.4 million |
PCVX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -185.9 million | 13.3 million |
| 2023-09-30 | -64.9 million | 13.2 million |
| 2023-06-30 | -60.6 million | 12.5 million |
| 2023-03-31 | -53.3 million | 9.6 million |
PCVX Net Income
No data available :(
PCVX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 1.1 billion | - | 29.2 million |
| 2023-09-30 | 1.3 billion | - | 13.8 million |
| 2023-06-30 | 1.3 billion | - | 15.2 million |
| 2023-03-31 | 949.9 million | - | 16.6 million |
PCVX Shares Outstanding
PCVX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 57.1 million | 104.2 million | 17.5 million | 2.9 million |
| 2023-09-30 | 7.3 million | 97.4 million | 15.6 million | - |
| 2023-06-30 | 2.1 million | 72.7 million | 14.5 million | - |
| 2023-03-31 | 5.6 million | 58.1 million | 13.1 million | - |
PCVX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | - | 2.9 million |
| 2023-09-30 | - | 2.5 million |
| 2023-06-30 | - | 2.4 million |
| 2023-03-31 | - | 2.3 million |
PCVX
Price: $60.55
52 week price:
Earnings Per Share: -4.14 USD
P/E Ratio: -15.82
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 346400
Market Capitalization: 6.7 billion